nach oben

Digestive Diseases and Sciences

Erschienen in:

16.09.2019 | Review

The Role of Gastrointestinal-Related Fatty Acid-Binding Proteins as Biomarkers in Gastrointestinal Diseases

verfasst von: Shaun S. C. Ho, Jacqueline I. Keenan, Andrew S. Day

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

The fatty acid-binding proteins play a major role in intracellular transportation of long-chain fatty acids. Nine fatty acid-binding proteins have been identified, with each having individual tissue-specific functions in addition to regulation of fatty acids. This review focuses on the three fatty acid-binding proteins found in the gastrointestinal tract and discusses their role as diagnostic or disease monitoring markers in neonatal necrotizing enterocolitis, acute mesenteric ischemia, celiac disease, and inflammatory bowel disease. Of these three fatty acid-binding proteins, intestinal fatty acid-binding protein is of the most interest due to its exclusive expression in the gastrointestinal tract. The elevation of intestinal fatty acid-binding protein in blood and urine reflects enterocyte damage, regardless of the underlying cause. The short half-life of intestinal fatty acid-binding protein also means it is a relatively sensitive marker. In contrast, there is currently less evidence to support liver fatty acid-binding protein and ileal bile acid-binding protein as sensitive biomarkers in these conditions. More extensive studies with specific endpoints are required to validate the roles of these fatty acid-binding proteins in gastrointestinal diseases.

Ockner RK, Manning JA, Poppenhausen RB, Ho WK. A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues. Science.. 1972;177:56–58.CrossRef

Chmurzynska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet.. 2006;47:39–48. https://doi.org/10.1007/BF03194597.CrossRefPubMed

Storch J, Thumser AE. Tissue-specific functions in the fatty acid-binding protein family. The Journal of biological Chem.. 2010;285:32679–32683. https://doi.org/10.1074/jbc.R110.135210.CrossRef

Rodriguez Sawicki L, Bottasso Arias NM, Scaglia N, et al. FABP1 knockdown in human enterocytes impairs proliferation and alters lipid metabolism. Biochim Biophys Acta Mol Cell Biol Lipids.. 2017;1862:1587–1594. https://doi.org/10.1016/j.bbalip.2017.09.006.CrossRefPubMed

Lagakos WS, Gajda AM, Agellon L, et al. Different functions of intestinal and liver-type fatty acid-binding proteins in intestine and in whole body energy homeostasis. Am J Physiol Gastrointest Liver Physiol.. 2011;300:G803–G814. https://doi.org/10.1152/ajpgi.00229.2010.CrossRefPubMedPubMedCentral

Bottasso Arias NM, Garcia M, Bondar C, et al. Expression Pattern of Fatty Acid Binding Proteins in Celiac Disease Enteropathy. Mediators Inflamm.. 2015;2015:738563. https://doi.org/10.1155/2015/738563.CrossRefPubMedPubMedCentral

Derikx JP, Vreugdenhil AC, Van den Neucker AM, et al. A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol.. 2009;43:727–733. https://doi.org/10.1097/MCG.0b013e31819194b0.CrossRefPubMed

Pelsers MMAL, Namiot Z, Kisielewski W, et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem.. 2003;36:529–535. https://doi.org/10.1016/S0009-9120%2803%2900096-1.CrossRefPubMed

Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov.. 2008;7:489–503. https://doi.org/10.1038/nrd2589.CrossRefPubMedPubMedCentral

10.

Praslickova D, Torchia EC, Sugiyama MG, et al. The ileal lipid binding protein is required for efficient absorption and transport of bile acids in the distal portion of the murine small intestine. PLoS One.. 2012;7:e50810. https://doi.org/10.1371/journal.pone.0050810.CrossRefPubMedPubMedCentral

11.

van de Poll MC, Derikx JP, Buurman WA, et al. Liver manipulation causes hepatocyte injury and precedes systemic inflammation in patients undergoing liver resection. World J Surg.. 2007;31:2033–2038. https://doi.org/10.1007/s00268-007-9182-4.CrossRefPubMedPubMedCentral

12.

Thumser AE, Moore JB, Plant NJ. Fatty acid binding proteins: tissue-specific functions in health and disease. Curr Opin Clin Nutr Metab Care.. 2014;17:124–129. https://doi.org/10.1097/MCO.0000000000000031.CrossRefPubMed

13.

Wang G, Bonkovsky HL, de Lemos A, Burczynski FJ. Recent insights into the biological functions of liver fatty acid binding protein 1. J Lipid Res.. 2015;56:2238–2247. https://doi.org/10.1194/jlr.R056705.CrossRefPubMedPubMedCentral

14.

Lin PW, Stoll BJ. Necrotising enterocolitis. Lancet.. 2006;368:1271–1283. https://doi.org/10.1016/S0140-6736(06)69525-1.CrossRefPubMed

15.

McGuire W, Anthony MY. Donor human milk versus formula for preventing necrotising enterocolitis in preterm infants: systematic review. Arch Dis Child Fetal Neonatal Ed.. 2003;88:F11–F14.CrossRef

16.

Lee JS, Polin RA. Treatment and prevention of necrotizing enterocolitis. Semin Neonatol.. 2003;8:449–459. https://doi.org/10.1016/S1084-2756(03)00123-4.CrossRefPubMed

17.

Yang G, Wang Y, Jiang X. Diagnostic value of intestinal fatty-acid-binding protein in necrotizing enterocolitis: a systematic review and meta-analysis. Indian J Pediatr.. 2016;83:1410–1419. https://doi.org/10.1007/s12098-016-2144-9.CrossRefPubMed

18.

Liu Y, Jiang L-F, Zhang R-P, Zhang W-T. Clinical significance of FABP2 expression in newborns with necrotizing enterocolitis. World J Pediatr WJP.. 2016;12:159–165. https://doi.org/10.1007/s12519-015-0035-1.CrossRefPubMed

19.

Cheng S, Yu J, Zhou M, Tu Y, Lu Q. Serologic intestinal-fatty acid binding protein in necrotizing enterocolitis diagnosis: a meta-analysis. BioMed Res Int.. 2015;2015:156704. https://doi.org/10.1155/2015/156704.CrossRefPubMedPubMedCentral

20.

Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis.. 2014;20:1407–1415. https://doi.org/10.1097/MIB.0000000000000057.CrossRefPubMed

21.

Reisinger KW, Van der Zee DC, Brouwers HAA, et al. Noninvasive measurement of fecal calprotectin and serum amyloid A combined with intestinal fatty acid-binding protein in necrotizing enterocolitis. J Pediatr Surg.. 2012;47:1640–1645. https://doi.org/10.1016/j.jpedsurg.2012.02.027.CrossRefPubMed

22.

Benkoe T, Baumann S, Weninger M, et al. Comprehensive evaluation of 11 cytokines in premature infants with surgical necrotizing enterocolitis. PLoS One.. 2013;8:e58720. https://doi.org/10.1371/journal.pone.0058720.CrossRefPubMedPubMedCentral

23.

Cho SX, Berger PJ, Nold-Petry CA, Nold MF. The immunological landscape in necrotising enterocolitis. Expert Rev Mol Med.. 2016;18:e12. https://doi.org/10.1017/erm.2016.13.CrossRefPubMedPubMedCentral

24.

Terrin G, Stronati L, Cucchiara S, De Curtis M. Serum markers of necrotizing enterocolitis: a systematic review. J Pediatr Gastroenterol Nutr.. 2017;65:e120–e132. https://doi.org/10.1097/MPG.0000000000001588.CrossRefPubMed

25.

Benkoe TM, Mechtler TP, Weninger M, Pones M, Rebhandl W, Kasper DC. Serum levels of interleukin-8 and gut-associated biomarkers in diagnosing necrotizing enterocolitis in preterm infants. J Pediatr Surg.. 2014;49:1446–1451. https://doi.org/10.1016/j.jpedsurg.2014.03.012.CrossRefPubMed

26.

27.

Ng EW, Poon TC, Lam HS, et al. Gut-associated biomarkers L-FABP, I-FABP, and TFF3 and LIT score for diagnosis of surgical necrotizing enterocolitis in preterm infants. Ann Surg.. 2013;258:1111–1118. https://doi.org/10.1097/SLA.0b013e318288ea96.CrossRefPubMed

28.

Aydemir C, Dilli D, Oguz SS, et al. Serum intestinal fatty acid binding protein level for early diagnosis and prediction of severity of necrotizing enterocolitis. Early Hum Dev.. 2011;87:659–661. https://doi.org/10.1016/j.earlhumdev.2011.05.004.CrossRefPubMed

29.

Schurink M, Kooi EMW, Hulzebos CV, et al. Intestinal fatty acid-binding protein as a diagnostic marker for complicated and uncomplicated necrotizing enterocolitis: a prospective cohort study. PLoS One.. 2015;10:e0121336. https://doi.org/10.1371/journal.pone.0121336.CrossRefPubMedPubMedCentral

30.

Evennett NJ, Hall NJ, Pierro A, Eaton S. Urinary intestinal fatty acid-binding protein concentration predicts extent of disease in necrotizing enterocolitis. J Pediatr Surg.. 2010;45:735–740. https://doi.org/10.1016/j.jpedsurg.2009.09.024.CrossRefPubMed

31.

Heida FH, Hulscher JBF, Schurink M, et al. Intestinal fatty acid-binding protein levels in Necrotizing Enterocolitis correlate with extent of necrotic bowel: results from a multicenter study. J Pediatr Surg.. 2015;50:1115–1118. https://doi.org/10.1016/j.jpedsurg.2014.11.037.CrossRefPubMed

32.

Clair DG, Beach JM. Mesenteric Ischemia. N Engl J Med.. 2016;374:959–968. https://doi.org/10.1056/NEJMra1503884.CrossRefPubMed

33.

Cudnik MT, Darbha S, Jones J, Macedo J, Stockton SW, Hiestand BC. The diagnosis of acute mesenteric ischemia: a systematic review and meta-analysis. Acad Emerg Med.. 2013;20:1087–1100. https://doi.org/10.1111/acem.12254.CrossRefPubMed

34.

Derikx JPM, Matthijsen RA, de Bruine AP, et al. Rapid reversal of human intestinal ischemia-reperfusion induced damage by shedding of injured enterocytes and reepithelialisation. PLoS One.. 2008;3:e3428. https://doi.org/10.1371/journal.pone.0003428.CrossRefPubMedPubMedCentral

35.

Schellekens DHSM, Grootjans J, Dello SAWG, et al. Plasma intestinal fatty acid-binding protein levels correlate with morphologic epithelial intestinal damage in a human translational ischemia-reperfusion model. J Clin Gastroenterol.. 2014;48:253–260. https://doi.org/10.1097/MCG.0b013e3182a87e3e.CrossRefPubMed

36.

Cronk DR, Houseworth TP, Cuadrado DG, Herbert GS, McNutt PM, Azarow KS. Intestinal fatty acid binding protein (I-FABP) for the detection of strangulated mechanical small bowel obstruction. Curr Surg.. 2006;63:322–325. https://doi.org/10.1016/j.cursur.2006.05.006.CrossRefPubMed

37.

Kittaka H, Akimoto H, Takeshita H, et al. Usefulness of intestinal fatty acid-binding protein in predicting strangulated small bowel obstruction. PLoS One.. 2014;9:e99915. https://doi.org/10.1371/journal.pone.0099915.CrossRefPubMedPubMedCentral

38.

Guzel M, Sozuer EM, Salt O, Ikizceli I, Akdur O, Yazici C. Value of the serum I-FABP level for diagnosing acute mesenteric ischemia. Surg Today.. 2014;44:2072–2076. https://doi.org/10.1007/s00595-013-0810-3.CrossRefPubMed

39.

Shi H, Wu B, Wan J, Liu W, Su B. The role of serum intestinal fatty acid binding protein levels and d-lactate levels in the diagnosis of acute intestinal ischemia. Clin Res Hepatol Gastroenterol.. 2015;39:373–378. https://doi.org/10.1016/j.clinre.2014.12.005.CrossRefPubMed

40.

Matsumoto S, Sekine K, Funaoka H, et al. Diagnostic performance of plasma biomarkers in patients with acute intestinal ischaemia. Br J Surg. 2014;101:232–238. https://doi.org/10.1002/bjs.9331.CrossRefPubMed

41.

Kanda T, Tsukahara A, Ueki K, et al. Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study. J Gastroenterol.. 2011;46:492–500. https://doi.org/10.1007/s00535-011-0373-2.CrossRefPubMed

42.

van der Voort PHJ, Westra B, Wester JPJ, et al. Can serum l-lactate, d-lactate, creatine kinase and I-FABP be used as diagnostic markers in critically ill patients suspected for bowel ischemia. BMC Anesthesiol.. 2014;14:111. https://doi.org/10.1186/1471-2253-14-111.CrossRefPubMedPubMedCentral

43.

Sun DL, Cen YY, Li SM, Li WM, Lu QP, Xu PY. Accuracy of the serum intestinal fatty-acid-binding protein for diagnosis of acute intestinal ischemia: a meta-analysis. Sci Rep.. 2016;6:34371. https://doi.org/10.1038/srep34371.CrossRefPubMedPubMedCentral

44.

Thuijls G, van Wijck K, Grootjans J, et al. Early diagnosis of intestinal ischemia using urinary and plasma fatty acid binding proteins. Ann Surg.. 2011;253:303–308. https://doi.org/10.1097/SLA.0b013e318207a767.CrossRefPubMed

45.

Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol.. 2018;16:823–836. https://doi.org/10.1016/j.cgh.2017.06.037.CrossRefPubMed

46.

Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet.. 2018;391:70–81. https://doi.org/10.1016/S0140-6736(17)31796-8.CrossRefPubMed

47.

Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol.. 1999;11:1185–1194.CrossRef

48.

Husby S, Koletzko S, Korponay-Szabo IR, et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr.. 2012;54:136–160. https://doi.org/10.1097/MPG.0b013e31821a23d0.CrossRefPubMed

49.

Tortora R, Imperatore N, Capone P, et al. The presence of anti-endomysial antibodies and the level of anti-tissue transglutaminases can be used to diagnose adult coeliac disease without duodenal biopsy. Aliment Pharmacol Ther.. 2014;40:1223–1229. https://doi.org/10.1111/apt.12970.CrossRefPubMed

50.

Efthymakis K, Serio M, Milano A, et al. Application of the biopsy-sparing ESPGHAN guidelines for celiac disease diagnosis in adults: a real-life study. Dig Dis Sci.. 2017;62:2433–2439. https://doi.org/10.1007/s10620-017-4672-1.CrossRefPubMed

51.

Adriaanse MPM, Tack GJ, Passos VL, et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther.. 2013;37:482–490. https://doi.org/10.1111/apt.12194.CrossRefPubMed

52.

Vreugdenhil AC, Wolters VM, Adriaanse MP, et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol.. 2011;46:1435–1441. https://doi.org/10.3109/00365521.2011.627447.CrossRefPubMed

53.

Adriaanse MPM, Mubarak A, Riedl RG, et al. Progress towards non-invasive diagnosis and follow-up of celiac disease in children; a prospective multicentre study to the usefulness of plasma I-FABP. Sci Rep.. 2017;7:8671. https://doi.org/10.1038/s41598-017-07242-4.CrossRefPubMedPubMedCentral

54.

Leonard MM, Weir DC, DeGroote M, et al. Value of IgA tTG in predicting mucosal recovery in children with celiac disease on a gluten-free diet. J Pediatr Gastroenterol Nutr.. 2017;64:286–291. https://doi.org/10.1097/MPG.0000000000001460.CrossRefPubMedPubMedCentral

55.

Sharkey LM, Corbett G, Currie E, Lee J, Sweeney N, Woodward JM. Optimising delivery of care in coeliac disease—comparison of the benefits of repeat biopsy and serological follow-up. Aliment Pharmacol Ther.. 2013;38:1278–1291. https://doi.org/10.1111/apt.12510.CrossRefPubMed

56.

Vecsei E, Steinwendner S, Kogler H, et al. Follow-up of pediatric celiac disease: value of antibodies in predicting mucosal healing, a prospective cohort study. BMC Gastroenterol.. 2014;14:28. https://doi.org/10.1186/1471-230X-14-28.CrossRefPubMedPubMedCentral

57.

Silvester JA, Kurada S, Szwajcer A, Kelly CP, Leffler DA, Duerksen DR. Tests for serum transglutaminase and endomysial antibodies do not detect most patients with celiac disease and persistent villous atrophy on gluten-free diets: a meta-analysis. Gastroenterology.. 2017;153:689–701. https://doi.org/10.1053/j.gastro.2017.05.015.CrossRefPubMedPubMedCentral

58.

Gidrewicz D, Trevenen CL, Lyon M, Butzner JD. Normalization time of celiac serology in children on a gluten-free diet. J Pediatr Gastroenterol Nutr.. 2017;64:362–367. https://doi.org/10.1097/MPG.0000000000001270.CrossRefPubMed

59.

Gross S, Adriaanse MP, Nijeboer P, et al. Serum intestinal-fatty acid binding protein as a biomarker for refractory celiac disease. J Gastrointest Liver Dis JGLD.. 2015;24:258–259.

60.

Oxentenko AS, Murray JA. Celiac disease: ten things that every gastroenterologist should know. Clin Gastroenterol Hepatol.. 2015;13:1396–1404. https://doi.org/10.1016/j.cgh.2014.07.024. quiz e127-9.CrossRefPubMed

61.

Murch S, Jenkins H, Auth M, et al. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children. Arch Dis Child.. 2013;98:806–811. https://doi.org/10.1136/archdischild-2013-303996.CrossRefPubMed

62.

Adriaanse MPM, Leffler DA, Kelly CP, et al. Serum I-FABP detects gluten responsiveness in adult celiac disease patients on a short-term gluten challenge. Am J Gastroenterol.. 2016;111:1014–1022. https://doi.org/10.1038/ajg.2016.162.CrossRefPubMed

63.

Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med.. 2009;361:2066–2078. https://doi.org/10.1056/NEJMra0804647.CrossRefPubMedPubMedCentral

64.

Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet.. 2012;380:1590–1605. https://doi.org/10.1016/S0140-6736(12)60026-9.CrossRefPubMed

65.

Goodhand J, Dawson R, Hefferon M, et al. Inflammatory bowel disease in young people: the case for transitional clinics. Inflamm Bowel Dis.. 2010;16:947–952. https://doi.org/10.1002/ibd.21145.CrossRefPubMed

66.

Levine A, de Bie CI, Turner D, et al. Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis.. 2013;19:370–377. https://doi.org/10.1002/ibd.23013.CrossRefPubMed

67.

Sarikaya M, Ergul B, Dogan Z, Filik L, Can M, Arslan L. Intestinal fatty acid binding protein (I-FABP) as a promising test for Crohn’s disease: a preliminary study. Clin Lab.. 2015;61:87–91.CrossRef

68.

Al-Saffar AK, Meijer CH, Gannavarapu VR, et al. Parallel changes in harvey-bradshaw index, TNFalpha, and intestinal fatty acid binding protein in response to infliximab in crohn’s disease. Gastroenterol Res Pract.. 2017;2017:1745918. https://doi.org/10.1155/2017/1745918.CrossRefPubMedPubMedCentral

69.

Bodelier AGL, Pierik MJ, Lenaerts K, et al. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol.. 2016;28:807–813. https://doi.org/10.1097/MEG.0000000000000616.CrossRefPubMed

70.

Wiercinska-Drapalo A, Jaroszewicz J, Siwak E, Pogorzelska J, Prokopowicz D. Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. Regul Pept.. 2008;147:25–28. https://doi.org/10.1016/j.regpep.2007.12.002.CrossRefPubMed

71.

Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Scand J Gastroenterol Suppl.. 1988;148:29–37.CrossRef

72.

Adriaanse MPM, van der Sande LJTM, van den Neucker AM, et al. Evidence for a cystic fibrosis enteropathy. PLoS One.. 2015;10:e0138062. https://doi.org/10.1371/journal.pone.0138062.CrossRefPubMedPubMedCentral

73.

Derikx JPM, Blijlevens NMA, Donnelly JP, et al. Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients. Ann Oncol Off J Eur Soc Med Oncol.. 2009;20:337–342. https://doi.org/10.1093/annonc/mdn579.CrossRef

74.

Kaufman SS, Lyden ER, Marks WH, et al. Lack of utility of intestinal fatty acid binding protein levels in predicting intestinal allograft rejection. Transplantation.. 2001;71:1058–1060.CrossRef

75.

Balesaria S, Pell RJ, Abbott LJ, et al. Exploring possible mechanisms for primary bile acid malabsorption: evidence for different regulation of ileal bile acid transporter transcripts in chronic diarrhoea. Eur J Gastroenterol Hepatol.. 2008;20:413–422. https://doi.org/10.1097/MEG.0b013e3282f41b82.CrossRefPubMed

76.

Relja B, Szermutzky M, Henrich D, et al. Intestinal-FABP and liver-FABP: Novel markers for severe abdominal injury. Acad Emerg Med Off J Soc Acad Emerg Med.. 2010;17:729–735. https://doi.org/10.1111/j.1553-2712.2010.00792.x.CrossRef

77.

Timmermans K, Sir O, Kox M, et al. Circulating iFABP Levels as a marker of intestinal damage in trauma patients. Shock (Augusta, Ga).. 2015;43:117–120. https://doi.org/10.1097/SHK.0000000000000284.CrossRef

78.

Shi J, Zhang Y, Gu W, et al. Serum liver fatty acid binding protein levels correlate positively with obesity and insulin resistance in Chinese young adults. PLoS One.. 2012;7:e48777. https://doi.org/10.1371/journal.pone.0048777.CrossRefPubMedPubMedCentral

79.

Gollin G, Stadie D, Mayhew J, et al. Early detection of impending necrotizing enterocolitis with urinary intestinal fatty acid-binding protein. Neonatology.. 2014;106:195–200. https://doi.org/10.1159/000362497.CrossRefPubMed

80.

Coufal S, Kokesova A, Tlaskalova-Hogenova H, Snajdauf J, Rygl M, Kverka M. Urinary intestinal fatty acid-binding protein can distinguish necrotizing enterocolitis from sepsis in early stage of the disease. J Immunol Res.. 2016;2016:5727312. https://doi.org/10.1155/2016/5727312.CrossRefPubMedPubMedCentral

81.

Thuijls G, Derikx JPM, van Wijck K, et al. Non-invasive markers for early diagnosis and determination of the severity of necrotizing enterocolitis. Ann Surg.. 2010;251:1174–1180. https://doi.org/10.1097/SLA.0b013e3181d778c4.CrossRefPubMed

82.

Gregory KE, Winston AB, Yamamoto HS, et al. Urinary intestinal fatty acid binding protein predicts necrotizing enterocolitis. J Pediatr.. 2014;164:1486–1488. https://doi.org/10.1016/j.jpeds.2014.01.057.CrossRefPubMedPubMedCentral

83.

Mannoia K, Boskovic DS, Slater L, Plank MS, Angeles DM, Gollin G. Necrotizing enterocolitis is associated with neonatal intestinal injury. J Pediatr Surg.. 2011;46:81–85. https://doi.org/10.1016/j.jpedsurg.2010.09.069.CrossRefPubMed

Titel: The Role of Gastrointestinal-Related Fatty Acid-Binding Proteins as Biomarkers in Gastrointestinal Diseases
verfasst von: Shaun S. C. Ho
Jacqueline I. Keenan
Andrew S. Day
Publikationsdatum: 16.09.2019
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 2/2020
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-019-05841-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Role of Gastrointestinal-Related Fatty Acid-Binding Proteins as Biomarkers in Gastrointestinal Diseases

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Oral Defense: How Oral Rehydration Solutions Revolutionized the Treatment of Toxigenic Diarrhea

Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma

Efficacy of Endoscopic Ultrasound-Guided Fine-Needle Biopsy in Gastric Subepithelial Tumors Located in the Cardia

Insulin-Like Growth Factor Binding Protein-Related Protein 1 Activates Primary Hepatic Stellate Cells via Autophagy Regulated by the PI3K/Akt/mTOR Signaling Pathway

Colonic Perforation as Initial Presentation of Amyloid Disease: Case Report and Literature Review

Downregulation of lncRNA NR2F2 Antisense RNA 1 Induces G1 Arrest of Colorectal Cancer Cells by Downregulating Cyclin-Dependent Kinase 6

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin